Amiel SA. The consequences of hypoglycaemia. Diabetologia. 2021;64(5):963–70. https://doi.org/10.1007/s00125-020-05366-3.
American Diabetes Association. 6. Glycemic goals and hypoglycaemia: standards of care in diabetes—2025. Diabetes Care. 2025;48(Supple. 1):S128–45. https://doi.org/10.2337/dc25-S006.
International Hypoglycaemia Study Group. Hypoglycaemia, cardiovascular disease, and mortality in diabetes: epidemiology, pathogenesis, and management. Lancet Diabetes Endocrinol. 2019;7:385–96.
Mellor J, Kuznetsov D, Heller S, Gall MA, Rosilio M, Amiel SA, et al. Estimating risk of consequences following hypoglycaemia exposure using the Hypo-RESOLVE cohort: a secondary analysis of pooled data from insulin clinical trials. Diabetologia. 2024;67(10):2210–24. https://doi.org/10.1007/s00125-024-06225-1.
Handelsman Y, Anderson JE, Bakris GL, Ballantyne CM, Bhatt DL, Bloomgarden ZT, et al. DCRM 2.0: multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases. Metabolism. 2024;159:155931. https://doi.org/10.1016/j.metabol.2024.155931.
Saisho Y. Glycemic variability and oxidative stress: a link between diabetes and cardiovascular disease? Int J Mol Sci. 2014;15(10):18381–406. https://doi.org/10.3390/ijms151018381.
Standl E, Khunti K, Hansen TB, Schnell O. The global epidemics of diabetes in the 21st century: current situation and perspectives. Eur J Prev Cardiol. 2019;26(Suppl. S2):7–14. https://doi.org/10.1177/2047487319881021.
IDF Diabetes Atlas International Diabetes Federation; 2025 [cited 2025 6/05/2025]. Available from: https://diabetesatlas.org/.diabres.2023.110945.
Zhou B. Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants. Lancet. 2024;404(10467):2077–93.
Holman RR, Sourij H, Califf RM. Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. Lancet. 2014;383(9933):2008–17. https://doi.org/10.1016/S0140-6736(14)60794-7.
Schnell O, Barnard-Kelly K, Battelino T, et al. CVOT summit report 2023: new cardiovascular, kidney, and metabolic outcomes. Cardiovasc Diabetol. 2024;23:104. https://doi.org/10.1186/s12933-024-02180-8.
Rick TJ. FDA’s new guidance for industry addressing evaluation of the safety of new drugs for improving glycemic control: a case study in regulatory science. Ther Innov Regul Sci. 2021;55(1):1–5.
FDA. Guidance for industry diabetes mellitus – evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes – guidance Document2008. Available from: https://www.regulations.gov/document/FDA-2008-D-0118-0029.
Standl E, Schnell O. Treatment paradigm shifting implications of recent cardiovascular outcome trials: core insights on the brink of the 2020ies. Diabetes Res Clin Pract. 2020;161:108054.
Heller SR, Geybels MS, Iqbal A, Liu L, Wagner L, Chow E. A higher non-severe hypoglycaemia rate is associated with an increased risk of subsequent severe hypoglycaemia and major adverse cardiovascular events in individuals with type 2 diabetes in the LEADER study. Diabetologia. 2022;65(1):55–64. https://doi.org/10.1007/s00125-021-05556-7.
Mellbin LG, Malmberg K, Waldenström A, Wedel H, Rydén L, DIGAMI 2 Investigators. Prognostic implications of hypoglycaemic episodes during hospitalisation for myocardial infarction in patients with type2 diabetes: a report from the DIGAMI 2 trial. Heart. 2009;95:721–7.
Mellbin LG, Rydén L, Riddle MC, ORIGIN Trial Investigators, et al. Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial. Eur Heart J. 2013;34:3137–44.
Pieber TR, Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, et al. Devote 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality. Diabetologia. 2018;61(1):58–65. https://doi.org/10.1007/s00125-017-4422-0.
Standl E, Stevens SR, Armstrong PW, TECOS Study Group, et al. Increased risk of severe hypoglycemic events before and after cardiovascular outcomes in TECOS suggests an at-risk type 2 diabetes frail patient phenotype. Diabetes Care. 2018;41:596–603. https://doi.org/10.2337/dc17-1778.
Wightman H, Butterly E, Wei L, McChrystal R, Sattar N, Adler A, et al. Frailty in randomized controlled trials of glucose-lowering therapies for type 2 diabetes: an individual participant data meta-analysis of frailty prevalence, treatment efficacy, and adverse events. PLoS Med. 2025;22(4):e1004553. https://doi.org/10.1371/journal.pmed.1004553.
Standl E, Stevens SR, Lokhnygina Y, EXSCEL Study Group, et al. Confirming the bidirectional nature of the association between severe hypoglycemic and cardiovascular events in type 2 diabetes: insights from EXSCEL. Diabetes Care. 2020;43(3):643–52. https://doi.org/10.2337/dc19-1079.
Rosenstock J, Kahn SE, Johansen OE, Zinman B, Espeland MA, Woerle HJ, et al. Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial. JAMA. 2019;322(12):1155–66. https://doi.org/10.1001/jama.2019.13772.
Rosenstock J, Perkovic V, Johansen OE, CARMELINA Investigators, et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA. 2019;321(1):69–79. https://doi.org/10.1001/jama.2018.18269.
Shi Q, Nong K, Vandvik PO, Guyatt GH, Schnell O, Rydén L, et al. Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2023;381:e074068. https://doi.org/10.1136/bmj-2022-074068.
The GRADE Study Research Group. Glycaemia reduction in type 2 diabetes—glycemic outcomes. N Engl J Med. 2022;387:1063–74.
The GRADE Study Research Group. Glycaemia reduction in type 2 diabetes—microvascular and cardiovascular outcomes. N Engl J Med. 2022;387:1075–88.
Rydén L, Standl E. After metformin—next steps for type 2 diabetes with low cardiovascular risk. N Engl J Med. 2022;387(12):1136–8. https://doi.org/10.1056/NEJMe2210531.
Duckworth W, Abraira C, Moritz T, et al. VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes [published correction appears in N Engl J Med 2009; 361:1028; N Engl J Med 2009; 361:1024–5]. N Engl J Med 2009; 360:129–39.
Zoungas S, Patel A, Chalmers J, ADVANCE Collaborative Group, et al. Severe hypoglycaemia and risks of vascular events and death. N Engl J Med. 2010;363:1410–8.
Bonds DE, Miller ME, Bergenstal RM, et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ. 2010;340:b4909.
Marx N, Kolkailah AA, Rosenstock J, Johansen OE, Cooper ME, Alexander JH, et al. Hypoglycaemia and cardiovascular outcomes in the CARMELINA and CAROLINA trials of linagliptin: a secondary analysis of randomized clinical trials. JAMA Cardiol. 2024;9(2):134–43. https://doi.org/10.1001/jamacardio.2023.4602.
Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ, et al. 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44:4043–140. https://doi.org/10.1093/eurheartj/ehad192.
Goto A, Arah OA, Goto M, Terauchi Y, Noda M. Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis. BMJ. 2013;347:f4533. https://doi.org/10.1136/bmj.f4533.
Zaccardi F, Ling S, Lawson C, Davies MJ, Khunti K. Severe hypoglycaemia and absolute risk of cause-specific mortality in individuals with type 2 diabetes: a UK primary care observational study. Diabetologia. 2020;63:2129–39.
Standl E, Schnell O. Increased risk of cancer-an integral component of the cardio-renal-metabolic disease cluster and its management. Cells. 2025;14(8):564. https://doi.org/10.3390/cells14080564.
Heller S, Lingvay I, Marso SP, Philis-Tsimikas A, Pieber TR, Poulter NR, et al. Risk of severe hypoglycaemia and its impact in type 2 diabetes in DEVOTE. Diabetes Obes Metab. 2020;22(12):2241–7. https://doi.org/10.1111/dom.14049.
Song SH, Frier BM. Severe hypoglycaemia and diabetic ketoacidosis in adults presenting to a hospital emergency department: adverse prognostic markers for survival in type 2 diabetes and the role of SGLT2 inhibitors. Diabet Med. 2025;42(3):e15466. https://doi.org/10.1111/dme.15466.
Cryer PE. Death during intensive glycemic therapy of diabetes: mechanisms and implications. Am J Med. 2011;124(11):993–6. https://doi.org/10.1016/j.amjmed.2011.08.008.
Tsujimoto T, Yamamoto-Honda R, Kajio H, et al. Vital signs, QT prolongation, and newly diagnosed cardiovascular disease during severe hypoglycaemia in type 1 and type 2 diabetic patients. Diabetes Care. 2014;37(1):217–25. https://doi.org/10.2337/dc13-0701.
Desouza C, Salazar H, Cheong B, Murgo J, Fonseca V. Association of hypoglycaemia and cardiac ischemia: a study based on continuous monitoring. Diabetes Care. 2003;26:1485–9.
Adler GK, Bonyhay I, Failing H, Waring E, Dotson S, Freeman R. Antecedent hypoglycaemia impairs autonomic cardiovascular function: implications for rigorous glycemic control. Diabetes. 2009;58:360–6.
Stahn A, Pistrosch F, Ganz X, et al. Relationship between hypoglycemic episodes and ventricular arrhythmias in patients with type 2 diabetes and cardiovascular diseases: silent hypoglycaemias and silent arrhythmias. Diabetes Care. 2014;37:516–20.
Iqbal A, Prince LR, Novodvorsky P, Bernjak A, Thomas MR, Birch L, et al. Effect of hypoglycemia on inflammatory responses and the response to low-dose endotoxemia in humans. J Clin Endocrinol Metab. 2019;104(4):1187–99. https://doi.org/10.1210/jc.2018-01168.
Chow E, Iqbal A, Walkinshaw E, Phoenix F, Macdonald IA, Storey RF, et al. Prolonged prothrombotic effects of antecedent hypoglycaemia in individuals with type 2 diabetes. Diabetes Care. 2018;41(12):2625–33. https://doi.org/10.2337/dc18-0050.
Verhulst CEM, van Heck JIP, Fabricius TW, Stienstra R, Teerenstra S, McCrimmon RJ, et al. Hypoglycaemia induces a sustained pro-inflammatory response in people with type 1 diabetes and healthy controls. Diabetes Obes Metab. 2023;25(11):3114–24. https://doi.org/10.1111/dom.15205.
Verhulst CEM, van Heck JIP, Fabricius TW, Stienstra R, Teerenstra S, McCrimmon RJ, et al. Sustained proinflammatory effects of hypoglycaemia in people with type 2 diabetes and in people without diabetes. Diabetes. 2022;71(12):2716–27. https://doi.org/10.2337/db22-0246.
Li G, Zhong S, Wang X, Zhuge F. Association of hypoglycaemia with the risks of arrhythmia and mortality in individuals with diabetes – a systematic review and meta-analysis. Front Endocrinol. 2023;14:1222409. https://doi.org/10.3389/fendo.2023.1222409.
Jordan J, Birkenfeld AL, Melander O, Moro C. Natriuretic peptides in cardiovascular and metabolic crosstalk: implications for hypertension management. Hypertension. 2018;72:270–6.
Coué M, Barquissau V, Morigny P, et al. Natriuretic peptides promote glucose uptake in a cGMP-dependent manner in human adipocytes. Sci Rep. 2018;8:1097.
Jungmann E, Konzok C, H¨oll E, Fassbinder W, Schöffling K. Effect of human atrial natriuretic peptide on blood glucose concentrations and hormone stimulation during insulin-induced hypoglycaemia in healthy man. Eur J Clin Pharmacol. 1989;36:593–7.
Standl E, Schnell O, McGuire DK. Heart failure considerations of antihyperglycemic medications for type 2 diabetes. Circ Res. 2016;118:1830–43.
Regan JA, Mentz RJ, Nguyen M, Green JB, Truby LK, Ilkayeva O, et al. Mitochondrial metabolites predict adverse cardiovascular events in individuals with diabetes. JCI Insight. 2023;8:e168563. https://doi.org/10.1172/jci.insight.168563.
Adler AI, Coleman RL, Leal J, Whiteley WN, Clarke P, Holman RR. Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 to 24 years (UKPDS 91). Lancet. 2024;404:145–55.
American Diabetes Association. Summary of revisions: standards of care in Diabetes—2025. Diabetes Care. 2025;48(Suppl. 1):S6–13. https://doi.org/10.2337/dc25-SREV.
Reaven PD, Newell M, Rivas S, Zhou X, Norman GJ, Zhou JJ. Initiation of continuous glucose monitoring is linked to improved glycemic control and fewer clinical events in type 1 and type 2 diabetes in the Veterans Health Administration. Diabetes Care. 2023;46(4):854–63. https://doi.org/10.2337/dc22-2189.
Nathanson D, Eeg-Olofsson K, Spelman T, et al. Intermittently scanned continuous glucose monitoring compared with blood glucose monitoring is associated with lower HbA1c and a reduced risk of hospitalisation for diabetes-related complications in adults with type 2 diabetes on insulin therapies. Diabetologia. 2025;68:41–51. https://doi.org/10.1007/s00125-024-06289-z.
Ajjan RA, Battelino T, Cos X, Del Prato S, Philips JC, Meyer L, et al. Continuous glucose monitoring for the routine care of type 2 diabetes mellitus. Nat Rev Endocrinol. 2024;20(7):426–40.
Battelino T, Lalic N, Hussain S, Ceriello A, Klobucar S, Davies SJ, et al. The use of continuous glucose monitoring in people living with obesity, intermediate hyperglycaemia or type 2 diabetes. Diabetes Res Clin Pract. 2025;223:112111. https://doi.org/10.1016/j.diabres.2025.112111.
Zhou X, Zeng C. Diabetes remission of bariatric surgery and nonsurgical treatments in type 2 diabetes patients who failure to meet the criteria for surgery: a systematic review and meta-analysis. BMC Endocr Disord. 2023;23:46. https://doi.org/10.1186/s12902-023-01283-9.
Borges-Canha M, Neves JS, Silva MM, et al. Prediabetes remission after bariatric surgery: a 4-years follow-up study. BMC Endocr Disord. 2024;24:7. https://doi.org/10.1186/s12902-024-01537-0.
Kahn SE, Deanfield JE, Jeppesen OK, Emerson SS, Boesgaard TW, Colhoun HM, et al. Effect of Semaglutide on regression and progression of glycaemia in people with overweight or obesity but without diabetes in the SELECT trial. Diabetes Care. 2024;47(8):1350–9. https://doi.org/10.2337/dc24-0491.
Jastreboff AM, le Roux CW, Stefanski A, Aronne LJ, Halpern B, Wharton S, et al. Tirzepatide for obesity treatment and diabetes prevention. N Engl J Med. 2025;392(10):958–71. https://doi.org/10.1056/NEJMoa2410819.
Lean ME, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, Kelly T, Irvine K, Peters C, Zhyzhneuskaya S. et al. 2024 5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study. Lancet Diabetes Endocrinol. 2024;12:233–46. Erratum in Lancet Diabetes Endocrinol. 12:e17.